Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 5:13:958665.
doi: 10.3389/fneur.2022.958665. eCollection 2022.

Clinical insights on the spasticity-plus syndrome in multiple sclerosis

Kanza Alami Marrouni  1   2 , Pierre Duquette  1   3
Affiliations

Clinical insights on the spasticity-plus syndrome in multiple sclerosis

Kanza Alami Marrouni et al. Front Neurol. .
No abstract available

Keywords: cannabinoids; multiple sclerosis; nabiximols; neuroimaging; spasticity; spasticity-plus syndrome; symptomatic therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
From the clinical evidence of MS symptomatic therapy with cannabinoids to the SPS. Clinical evidence was retrieved from systematic literature reviews by Filippini et al. (5) and Landrigan et al. (6). MS, spasticity; AEs, adverse events; HRQoL, health-related quality of life; SAEs, serious adverse events; SPS, spasticity-plus syndrome; DIT, diffusion imaging tractography; rsfMRI, resting-state functional magnetic resonance imaging. Created with BioRender.com.
See this image and copyright information in PMC

References

    1. Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. . Multiple Sclerosis. Nat Rev Dis Primers. (2018) 4:43. 10.1038/s41572-018-0041-4 - DOI - PubMed
    1. Fernández O, Costa-Frossard L, Martínez-Ginés M, Montero P, Prieto JM, Ramió L. The broad concept of “Spasticity-Plus Syndrome” in multiple sclerosis: a possible new concept in the management of multiple sclerosis symptoms. Front Neurol. (2020) 11:152. 10.3389/fneur.2020.00152 - DOI - PMC - PubMed
    1. Bruno A, Dolcetti E, Centonze D. Theoretical and therapeutic implications of the spasticity-plus syndrome model in multiple sclerosis. Front Neurol. (2022) 12:802918. 10.3389/fneur.2021.802918 - DOI - PMC - PubMed
    1. Fernández O, Costa-Frossard L, Martínez-Ginés ML, Montero P, Prieto-González JM, Ramió-Torrentà L. Integrated management of multiple sclerosis spasticity and associated symptoms using the spasticity-plus syndrome concept: results of a structured specialists' discussion using the Workmat® Methodology. Front Neurol. (2021) 12:722801. 10.3389/fneur.2021.722801 - DOI - PMC - PubMed
    1. Filippini G, Minozzi S, Borrelli F, Cinquini M, Dwan K. Cannabis and Cannabinoids for symptomatic treatment for people with multiple sclerosis. Cochrane Database Syst Rev. (2022) 5:CD013444. 10.1002/14651858.CD013444.pub2 - DOI - PMC - PubMed

LinkOut - more resources